BrightPath Biotherapeutics Co., Ltd. (4594.T) Comparison with companies in other sectors?

BrightPath Biotherapeutics Co., Ltd. has a share price of 116.03M. You can analyze BrightPath Biotherapeutics Co., Ltd. (4594.T) competitors across different market sectors through stock heatmaps.

What are 4594.T's NET and operating margins?

BrightPath Biotherapeutics Co., Ltd. (4594.T) operating margin is around -1024.64, and net profit margin is approximately -1016.02 as of the latest reports.

In what way does 4594.T's earnings per share (EPS) trend reflect its financial momentum?

BrightPath Biotherapeutics Co., Ltd. (4594.T) EPS is -14.12 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for BrightPath Biotherapeutics Co., Ltd. is -5.10, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for BrightPath Biotherapeutics Co., Ltd.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for BrightPath Biotherapeutics Co., Ltd. like P/E which is -5.50, P/B which is 6.84, and PEG which is 1.14. Compare them with sector averages to evaluate if the stock is priced fairly.

BrightPath Biotherapeutics Co., Ltd.

4594.T•JPX

Healthcare

Biotechnology

¥72.00

¥-3.00(-4.00%)

BrightPath Biotherapeutics Co., Ltd. (4594.T) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-14.12

P/E Ratio

-5.10

ROE

-1.16%

Net Margin

-1016.02%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$8.35B

Shares OutstandingTotal number of shares issued

$116.03M

Book Value/ShareNet worth per share

$10.53

Revenue/ShareAnnual revenue per share

$0.01

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-14.12

Net MarginNet income as percentage of revenue

-101601.85%

Operating MarginOperating income as percentage of revenue

-102464.08%

ROEReturn on shareholders' equity

-116.20%

ROAReturn on total assets

-102.73%

ROCEReturn on capital employed

-117.39%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.006

Cash/ShareCash and equivalents per share

$9.22

FCF YieldFree cash flow as percentage of market cap

0.006%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 4594.TFinancial Ratios Analysis details for 4594.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 4594.TSector Benchmarking details for 4594.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for BrightPath Biotherapeutics Co., Ltd. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of BrightPath Biotherapeutics Co., Ltd.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account BrightPath Biotherapeutics Co., Ltd.'s unique business strengths and challenges.

Key Financial Metrics for BrightPath Biotherapeutics Co., Ltd.

For BrightPath Biotherapeutics Co., Ltd., essential financial indicators include EPS -14.12, PE -5.10, and ROE -1.16. These key ratios reveal insights into BrightPath Biotherapeutics Co., Ltd.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare BrightPath Biotherapeutics Co., Ltd. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of BrightPath Biotherapeutics Co., Ltd.

Metrics like Net Margin -101601.85% and ROA -102.73% shed light on how well BrightPath Biotherapeutics Co., Ltd. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether BrightPath Biotherapeutics Co., Ltd. can sustain its operations and continue growing in the future.

Valuation and Market Position of BrightPath Biotherapeutics Co., Ltd.

Using ratios such as P/B Ratio 6.84 and PEG Ratio 1.14, investors can assess whether BrightPath Biotherapeutics Co., Ltd. is appropriately valued based on its financials and growth potential. These figures, combined with BrightPath Biotherapeutics Co., Ltd.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for BrightPath Biotherapeutics Co., Ltd.

Financial health indicators, such as Debt/Equity Ratio 0.03 and Cash Flow $0.006, provide a snapshot of BrightPath Biotherapeutics Co., Ltd.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like BrightPath Biotherapeutics Co., Ltd., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for BrightPath Biotherapeutics Co., Ltd.

Investing in BrightPath Biotherapeutics Co., Ltd. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at BrightPath Biotherapeutics Co., Ltd. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;